logo ct-atlantic








Our Team : Management | Board of Directors | Scientific Advisors

Board of Directors

Prof. Alexander Knuth, Scientific Founder, Chairman of the Board
Alexander Knuth is the founder of CT Atlantic and Chairman of the Department of Oncology at University Hospital, Zurich, Switzerland. A pioneer in the field of tumor immunotherapy, Prof. Knuth is widely recognized as one of Europe's leading clinical oncologists and immunology-focused cancer researchers.

Prof. Knuth also currently heads the Clinical Trials Center at University Hospital, Zurich, Switzerland and the associated research activities supported by the Ludwig Institute for Cancer Research (LICR) and Cancer Research Institute (CRI). In addition, Prof. Knuth plays a key role in the Cancer Vaccine Collaborative of CRI and LICR. Prof. Knuth has received numerous scientific accolades and is an advisor to a number of industrial and governmental organizations.

Dr Karsten Henco
Karsten Henco is one of Europe’s most successful serial scientific entrepreneurs. In addition to his investing and coaching activities for Biotech start-ups, Dr. Henco brings tremendous experience in the biopharmaceutical industry to CT Atlantic.

Dr. Henco is a co-founder of HS LifeSciences and QureInvest and was Managing Director and CEO of U3 Pharma (Munich, Germany) and Evotec AG (Hamburg, Germany). Before founding Evotec AG, Dr. Henco co-founded Qiagen NV and served as Managing Partner for the company. He is co-founder or co-founding investor of a number of biotech companies in Germany, USA and Austria and a board member of the DIB - the Organization of the German Biotech Industry.

Dr Edward Stuart
Edward Stuart was the founding CEO of CT Atlantic and brings significant experience in business development for biotechnology start-ups to CT Atlantic.

Dr. Stuart is a co-founder of HS LifeSciences and QureInvest and previously CEO of Neurimmune Therapeutics (Zurich, Switzerland). He was also a co-founder of U3 Pharma (Munich, Germany) and was its Managing Director and CBO from 2001 to 2007. Dr. Stuart is a pharmacologist by training having received his PhD from University College Dublin, Ireland and holds an MBA from the Business School of Imperial College, London (London, UK).

Dr Jill O’Donnell-Tormey, Non-Voting Member
Jill O’Donnell-Tormey, Ph.D., is the Executive Director of the Cancer Research Institute (CRI), a nonprofit organization dedicated to support and coordinate new and effective immune system-based strategies for cancer. Prior to her leadership roles at the Cancer Research Institute, Dr. O’Donnell served as an instructor in the department of medicine at Cornell University Medical College and as a research associate in the laboratory of cellular physiology and immunology at The Rockefeller University.

Dr. O’Donnell-Tormey has played a critical role at the CRI in promoting the development of novel cancer therapeutics through her oversight of the Clinical Investigation Program, the Cancer Vaccine Collaborative, the Cancer Immunotherapy Consortium, and the Cancer Vaccine Acceleration Fund, a new CRI venture philanthropy fund dedicated to expediting the development of therapeutic cancer vaccines. Dr. O’Donnell holds a doctor of philosophy in cell biology from The State University of New York’s Downstate Medical Center and is the recipient of numerous awards and accolades.